KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Non-Current Liabilities (2016 - 2025)

CRISPR Therapeutics AG's Total Non-Current Liabilities history spans 11 years, with the latest figure at $337.3 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 10.04% year-over-year to $337.3 million; the TTM value through Dec 2025 reached $337.3 million, up 10.04%, while the annual FY2025 figure was $337.3 million, 10.04% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $337.3 million at CRISPR Therapeutics AG, up from $324.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $394.1 million in Q3 2022 and bottomed at $144.3 million in Q1 2021.
  • The 5-year median for Total Non-Current Liabilities is $345.4 million (2021), against an average of $332.3 million.
  • The largest annual shift saw Total Non-Current Liabilities soared 145.31% in 2022 before it fell 11.58% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $345.1 million in 2021, then grew by 4.79% to $361.6 million in 2022, then fell by 4.37% to $345.8 million in 2023, then dropped by 11.36% to $306.5 million in 2024, then grew by 10.04% to $337.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Total Non-Current Liabilities are $337.3 million (Q4 2025), $324.0 million (Q3 2025), and $314.1 million (Q2 2025).